Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2020-12-09 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于对《云南证监局关于沃森生物的问询函》（云证监函[2020]265号）回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company (Yunnan Watson Biotechnology Co., Ltd.) responding to an inquiry letter from the Yunnan Securities Regulatory Bureau. It discusses in depth the company's strategic decisions regarding equity transfers, capital increases, convertible debt, and investment fund structures related to its subsidiary Shanghai Zerun Biotechnology Co., Ltd. The content includes detailed explanations of investment decisions, shareholding structures, regulatory compliance, and related-party transactions. There is no indication that this is a full annual or interim financial report, earnings release, or audit report. Instead, it is a regulatory response to a formal inquiry letter, providing clarifications and disclosures about corporate actions and compliance matters. The document is lengthy and substantive but primarily serves as a regulatory filing responding to a regulatory inquiry rather than a financial report or earnings announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2020-12-09 Chinese
关于对深圳证券交易所创业板关注函[2020]第526号回复的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company (Yunnan Watson Biotechnology Co., Ltd.) responding to a regulatory inquiry from the Shenzhen Stock Exchange regarding a significant transaction involving the transfer and investment in a subsidiary (Shanghai Zerun Biotechnology Co., Ltd.). The content includes detailed disclosures about the transaction, the involved parties, their financials, ownership structures, and strategic rationale. It is a regulatory response document addressing concerns raised by the exchange about a capital/financing transaction, specifically a share transfer and capital increase involving private equity investors. The document does not contain a full annual or quarterly financial report, audit report, earnings release, or other types of reports. It is not a simple announcement of a report publication but a substantive regulatory filing responding to an official inquiry. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and compliance documents that do not fit other specific categories.
2020-12-08 Chinese
关于收到云南证监局问询函和深圳证券交易所关注函的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from a company (云南沃森生物技术股份有限公司) regarding receipt of an inquiry letter from the Yunnan Securities Regulatory Bureau and a letter of concern from the Shenzhen Stock Exchange. The content focuses on detailed questions about a significant equity transfer and capital increase transaction involving a subsidiary (上海泽润生物科技有限公司), including requests for explanations on transaction rationale, related party relationships, financial and operational impacts, compliance with regulations, and corporate governance matters. The document is a regulatory inquiry response and disclosure rather than a financial report, earnings release, or management discussion. It does not contain financial statements or earnings highlights but is a regulatory filing addressing compliance and disclosure issues. The document length (9842 characters) and detailed nature confirm it is not a brief announcement of a report publication. It is not a certification letter or officer attestation. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2020-12-07 Chinese
关于取消审议2020年第六次临时股东大会部分议案的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company regarding the cancellation of the review of certain proposals at a specific shareholders' meeting (the 2020 sixth extraordinary general meeting). It discusses board decisions and shareholder meeting agenda changes, specifically about a share transfer and capital increase agreement. The document does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an official announcement related to shareholder meeting agenda changes and corporate actions. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-12-07 Chinese
关于召开2020年第六次临时股东大会的通知（更新后）
AGM Information Classification · 95% confidence The document is a detailed notice about convening the 2020 sixth extraordinary general meeting (临时股东大会) of Yunnan Watson Biotechnology Co., Ltd. It includes information about the meeting date, voting procedures, registration, and agenda items. It does not contain financial statements or results but is an announcement of a shareholders meeting and related voting information. The document length is 4162 characters, which is relatively short and consistent with a meeting notice rather than a full report. There is no indication of voting results or financial disclosures. Therefore, this document fits the category of AGM Information (AGM-R), which covers presentations and materials shared during or about the Annual or Extraordinary General Meeting, including meeting notices and agendas.
2020-12-07 Chinese
第四届董事会第十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of a board meeting resolution by the company Yunnan Watson Biotechnology Co., Ltd. It details the convening of the fourth board's seventeenth meeting, the agenda discussed, and the voting results. There is no financial data, earnings information, or detailed report content. The document is an announcement of board decisions and meeting outcomes, which fits the category of Board/Management Information (MANG). The document length is short and focused on board resolutions, not a full report or regulatory filing. Therefore, the classification is MANG with high confidence.
2020-12-07 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.